Related Experiment Video
Updated: May 30, 2026
13:36
Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation
Published on: July 23, 2012
Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas.
Lars Fischer1, Michael Hummel, Agnieszka Korfel
1Department of Hematology and Oncology, Charité Universitätsmedizin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. lars.fischer@charite.de
Neuro-Oncology
|August 2, 2011
Summary
Primary CNS lymphoma (PCNSL) shows distinct micro-RNA (miRNA) expression compared to nodal DLBCL. These miRNA differences suggest unique molecular pathways drive PCNSL pathogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Primary CNS lymphoma (PCNSL) and nodal DLBCL (nDLBCL) are both diffuse large B-cell lymphomas but exhibit different clinical behaviors and prognoses.
- The precise pathogenesis of PCNSL remains incompletely understood.
- Micro-RNAs (miRNAs) are implicated in cancer development and progression.
Purpose of the Study:
- To investigate differential miRNA expression between PCNSL and nDLBCL.
- To identify novel molecular mechanisms potentially involved in PCNSL pathogenesis.
Main Methods:
- Quantitative real-time PCR was used to measure the expression of 365 miRNA species.
- Low-density PCR arrays were employed.
- Paraffin-embedded biopsy specimens from 21 HIV-negative patients (11 PCNSL, 10 nDLBCL) were analyzed.
Main Results:
- Eighteen miRNAs were found to be differentially expressed between PCNSL and nDLBCL.
- Thirteen miRNAs were upregulated in PCNSL, associated with the Myc pathway, B-cell differentiation blockade, or inflammatory cytokine response.
- Five miRNAs were upregulated in nDLBCL. Putative tumor-suppressor miRNAs were downregulated in PCNSL.
Conclusions:
- PCNSL exhibits a distinct miRNA expression profile compared to nDLBCL.
- These findings suggest different molecular mechanisms underlie the pathogenesis of PCNSL and nDLBCL.
- The identified miRNAs may represent novel therapeutic targets or biomarkers for PCNSL.
